ABSTRACT
Purpose:
Osteoporosis is a bone disease which commonly occurred in postmenopausal women. Almost 10 percent of world population and approximately 30% of women (postmenopausal) suffer from this disease. Alternative medicine has great success in the treatment of osteoporosis disease. Bryodulcosigenin, a potent phytoconstituent, already displayed the anti-inflammatory and antioxidant effect. In this study, we made effort to analyze the antiosteoporosis effect of bryodulcosigenin against ovariectomy (OVX) induced osteoporosis in rats.
Methods:
Swiss albino Wistar rats were grouped into fIve groups and given an oral dose of bryodulcosigenin (10, 20 and 30 mg/kg) for eight weeks. Body weight, uterus, bone mineral density, cytokines, hormones parameters, transforming growth factor (TGF)-β, insulin-like growth factor (IGF), osteoprotegerin (OPG), receptor activator of nuclear factor kappa-Β ligand (RANKL), and its ratio were estimated.
Results:
Bryodulcosigenin significantly (p < 0.001) suppressed the body weight and enhanced the uterine weight and significantly (p < 0.001) increased the bone mineral density in whole femur, caput femoris, distal femur and proximal femur. Bryodulcosigenin significantly (P < 0.001) altered the level of biochemical parameters at dose dependent manner, significantly (P < 0.001) improved the level of estrogen and suppressed the level of follicle stimulating hormone and luteinizing hormone. Bryodulcosigenin significantly (P < 0.001) improved the level of OPG and suppressed the level of RANKL.
Conclusions:
Bryodulcosigenin reduced the cytokines level and suppressed the TGF-β and IGF. We concluded that bryodulcosigenin is an antiosteoporosis medication based on the findings.
Key words
Bone diseases; Osteoporosis; Inflammation; Hormones
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
OVX: ovariectomy; *P < 0.05, **P < 0.01 and ***P < 0.001 were considered as significant.
OVX: ovariectomy; *P < 0.05, **P < 0.01 and ***P < 0.001 were considered as significant.
OVX: ovariectomy; OT: oxytocin; bALP: bone-specific alkaline phosphatase; TRAP: tartrate-resistant acid phosphatase; CTX: Cterminal telopeptide of type I collagen; *P < 0.05, **P < 0.01 and ***P < 0.001 were considered as significant.
OVX: ovariectomy; *P < 0.05, **P < 0.01 and ***P < 0.001 were considered as significant.
OVX: ovariectomy; OPG: osteoprotegerin; RANKL: receptor activator of nuclear factor kappa-Β ligand; *P < 0.05, **P < 0.01 and ***P < 0.001 were considered as significant.
OVX: ovariectomy; TGF: transforming growth factor; IGF: insulin-like growth factor; *P < 0.05, **P < 0.01 and ***P < 0.001 were considered as significant.
OVX: ovariectomy; TNF-α: tumor necrosis factor-α; IL-1β: interleukin-1β; IL-6: interleukin-6; IFN-γ: interferon-gamma; *P < 0.05, **P < 0.01 and ***P < 0.001 were considered as significant.